OTCM
QNNTF
Market cap6mUSD
Apr 22, Last price
0.10USD
Name
Quantum Genomics SA
Chart & Performance
P/E
—
P/S
309.24
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
20k
Net income
-3m
CFO
0k
Profile
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY |
|---|---|
| 2023‑12 | |
| Income | |
Revenues | 20 |
Cost of revenue | 1,439 |
Unusual Expense (Income) | |
NOPBT | (1,419) |
NOPBT Margin | |
Operating Taxes | (34) |
Tax Rate | |
NOPAT | (1,385) |
Net income | (3,171) |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | 757 |
Long-term debt | 1,960 |
Deferred revenue | |
Other long-term liabilities | 2 |
Net debt | (871) |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | 3,547 |
Long term investments | 41 |
Excess cash | 3,587 |
Stockholders' equity | (14,171) |
Invested Capital | 17,324 |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | 34,857 |
Price | |
Market cap | |
EV | |
EBITDA | (1,419) |
EV/EBITDA | |
Interest | 21 |
Interest/NOPBT | |